Cardiovascular Safety of β3 -adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome

Abstract Context Mirabegron, the first β3 -adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (OAB) syndrome symptoms. Because β3 -adrenoceptors are expressed in cardiovascular (CV) tissues, there are concerns that OAB treatment with β3 -adrenoceptor agonists...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European urology 2016-02, Vol.69 (2), p.311-323
Hauptverfasser:	Rosa, Gian Marco, Ferrero, Simone, Nitti, Victor W, Wagg, Adrian, Saleem, Tahir, Chapple, Christopher R
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetanilides - adverse effects Adrenergic beta-3 Receptor Agonists - adverse effects Aniline Compounds - adverse effects Benzoates - adverse effects Biphenyl Compounds - adverse effects Blood Pressure - drug effects Cardiovascular Cardiovascular Diseases - chemically induced Electrocardiography - drug effects Heart Rate - drug effects Humans Overactive bladder Safety Thiazoles - adverse effects Urinary Bladder, Overactive - drug therapy Urology β3-Adrenoceptor agonist
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!